uploads/2018/02/Pulmonary-hypertension-1.png

How JNJ’s Hypertension Segment Performed in 4Q17

By

Updated

Pulmonary Hypertension’s revenue trends

Johnson & Johnson (JNJ) established its Pulmonary Hypertension segment by the acquisition of Actelion Ltd in June 2017. In 4Q17, Johnson & Johnson’s (JNJ) Pulmonary Hypertension portfolio reported revenues of $610.0 million. In 4Q17, in the US market and the international markets, JNJ’s Pulmonary Hypertension segment generated revenues of $365.0 million and $245.0 million, respectively, which reflected an ~9.0% quarter-over-quarter decline.

In fiscal 2017, JNJ’s Pulmonary Hypertension segment reported net revenues of $1.3 billion. In 2017, in the US market and international markets, JNJ’s pulmonary hypertension drugs generated revenues of $773.0 million and $554.0 million, respectively.

Article continues below advertisement

Opsumit’s revenue trends

In 4Q17, JNJ’s Opsumit generated revenues of $269.0 million, which is ~4.0% growth on a quarter-over-quarter basis. In 4Q17, in the US and international markets, Opsumit reported revenues of $146.0 million and $123.0 million, respectively.

In fiscal 2017, Opsumit reported revenues of $573.0 million. In 2017, in the US market and international markets, Opsumit generated revenues of $320.0 million and $253.0 million, respectively.

Tracleer’s revenue trends

In 4Q17, Tracleer generated revenues of $167.0 million, which is an ~20.0% decline on a YoY basis. In 4Q17, in the US and international markets, Tracleer generated revenues of $76.0 million and $91.0 million, respectively.

In fiscal 2017, Tracleer reported revenues of $403.0 million, including $161.0 million and $242.0 million from the US and international markets, respectively.

Uptravi’s revenue trends

In 4Q17, Uptravi generated revenues of $130.0 million, which is ~5.0% growth on a quarter-over-quarter basis. In 4Q17, in the US and international markets, Uptravi reported revenues of $117.0 million and $13.0 million, respectively.

In 2017, Uptravi generated revenues of $236.0 million. In 2017, in the US and international markets, Uptravi generated revenues of $238.0 million and $25.0 million, respectively.

Some important drugs in the PAH market include Gilead Sciences’ (GILD) Letairis, Pfizer’s (PFE) Norvasc, United Therapeutics’ (UTHR) Remodulin, Orenitram, and Tyvaso, and Bayer’s (BAYZF) Adempas.

Advertisement

More From Market Realist